The Challenges of Eradicating Pediatric Helicobacter pylori Infection in the Era of Probiotics

Helicobacter pylori (H. pylori), the most common infection of childhood, results in life-threatening complications during adulthood if left untreated. Most of these complications are related to H. pylori-induced chronic inflammation. The dysbiosis caused by H. pylori is not limited to the gastric microenvironment, but it affects the entire gastrointestinal tract. Eradication of H. pylori has recently become a real challenge for clinicians due to both the persistent increase in antibiotic resistance worldwide and the wide spectrum of side effects associated with the eradication regimens resulting; therefore, there is an urgent need for more effective and less noxious treatment options. Thus, probiotics might be a promising choice in both adults and children with H. pylori infection since their role in improving the eradication rate of this infection has been proved in multiple studies. The positive effects of probiotics might be explained by their abilities to produce antimicrobial compounds and antioxidants, alter local gastric pH, and subsequently decrease H. pylori colonization and adherence to gastric epithelial cells. Nevertheless, if used alone probiotics do not considerably increase the eradication rate.

[1]  C. Mărginean,et al.  The Yin-Yang Concept of Pediatric Obesity and Gut Microbiota , 2022, Biomedicines.

[2]  C. Bănescu,et al.  Innate Immune Responses in Pediatric Patients with Gastritis—A Trademark of Infection or Chronic Inflammation? , 2022, Children.

[3]  Alina Boglis,et al.  Innate immunity – the hallmark of Helicobacter pylori infection in pediatric chronic gastritis , 2021, World journal of clinical cases.

[4]  C. Mărginean,et al.  Gastric Microenvironment—A Partnership between Innate Immunity and Gastric Microbiota Tricks Helicobacter pylori , 2021, Journal of clinical medicine.

[5]  R. Nasr,et al.  The Crosstalk between Microbiome and Immune Response in Gastric Cancer , 2020, International journal of molecular sciences.

[6]  L. Kupčinskas,et al.  Transient and Persistent Gastric Microbiome: Adherence of Bacteria in Gastric Cancer and Dyspeptic Patient Biopsies after Washing , 2020, Journal of clinical medicine.

[7]  Peng-Chieh Chen,et al.  Probiotics-Containing Yogurt Ingestion and H. pylori Eradication Can Restore Fecal Faecalibacterium prausnitzii Dysbiosis in H. pylori-Infected Children , 2020, Biomedicines.

[8]  J. Gisbert,et al.  Systematic review: gastric microbiota in health and disease , 2020, Alimentary pharmacology & therapeutics.

[9]  Alina Boglis,et al.  The relationship between TLR4 rs4986790 and rs4986791 gene polymorphisms and Helicobacter pylori infection in children with gastritis. , 2019, Pathology, research and practice.

[10]  A. Falanga,et al.  Beta-defensins and analogs in Helicobacter pylori infections: mRNA expression levels, DNA methylation, and antibacterial activity , 2019, PloS one.

[11]  S. Laneri,et al.  A Novel View of Human Helicobacter pylori Infections: Interplay between Microbiota and Beta-Defensins , 2019, Biomolecules.

[12]  C. Mărginean,et al.  The Relationship between Toll-like Receptors and Helicobacter pylori-Related Gastropathies: Still a Controversial Topic , 2019, Journal of immunology research.

[13]  Y. Xiong,et al.  Analysis of culturable microbiota present in the stomach of children with gastric symptoms , 2018, Brazilian Journal of Microbiology.

[14]  H. Yonezawa,et al.  Role of Probiotics in Eradication Therapy for Helicobacter pylori Infection. , 2019, Advances in experimental medicine and biology.

[15]  J. G. Kusters,et al.  Future of Helicobacter pylori and its feasibility , 2018, Expert review of anti-infective therapy.

[16]  B. Johnston,et al.  Probiotics to Prevent Clostridium difficile Infection in Patients Receiving Antibiotics. , 2018, JAMA.

[17]  D. Bravo,et al.  Helicobacter pylori in human health and disease: Mechanisms for local gastric and systemic effects. , 2018, World journal of gastroenterology.

[18]  M. Barone,et al.  Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis , 2018, World journal of gastroenterology.

[19]  J. L. Costa,et al.  Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota , 2017, Gut.

[20]  T. Alarcón,et al.  Helicobacter pylori treatment: antibiotics or probiotics , 2017, Applied Microbiology and Biotechnology.

[21]  Jianhua He,et al.  Probiotics in 14-day triple therapy for Asian pediatric patients with Helicobacter pylori infection: a network meta-analysis , 2017, Oncotarget.

[22]  Jing Liu,et al.  Probiotics in Helicobacter pylori eradication therapy: Systematic review and network meta-analysis. , 2017, Clinics and research in hepatology and gastroenterology.

[23]  F. Bäckhed,et al.  Evolution, human-microbe interactions, and life history plasticity , 2017, The Lancet.

[24]  Jing Liu,et al.  Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis , 2017, European Journal of Clinical Pharmacology.

[25]  A. Evans,et al.  Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis. , 2017, Gastroenterology.

[26]  Banu N Şirvan,et al.  Are Synbiotics added to the Standard Therapy to eradicate Helicobacter pylori in Children Beneficial? A Randomized Controlled Study , 2017, Euroasian journal of hepato-gastroenterology.

[27]  N. Lu,et al.  Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance , 2017, Frontiers in cellular and infection microbiology.

[28]  Linda M Krisch,et al.  From inflammation to gastric cancer – the importance of Hedgehog/GLI signaling in Helicobacter pylori-induced chronic inflammatory and neoplastic diseases , 2017, Cell Communication and Signaling.

[29]  Zhan Gao,et al.  Characterization of the Gastric Microbiota in a Pediatric Population According to Helicobacter pylori Status , 2017, The Pediatric infectious disease journal.

[30]  E. Lefkowitz,et al.  Helicobacter pylori Infection is Associated with an Altered Gastric Microbiota in Children , 2016, Mucosal Immunology.

[31]  R. Peek,et al.  DNA Transfer and Toll-like Receptor Modulation by Helicobacter pylori. , 2017, Current topics in microbiology and immunology.

[32]  Antonio Gasbarrini,et al.  Antibiotics as deep modulators of gut microbiota: between good and evil , 2016, Gut.

[33]  P. Malfertheiner,et al.  Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events , 2016, United European gastroenterology journal.

[34]  Bong-Soo Kim,et al.  The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial , 2016, Helicobacter.

[35]  H. Adanir,et al.  Local Immune Response in Helicobacter pylori Infection , 2016, Medicine.

[36]  Li Yang,et al.  Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review , 2016, American journal of therapeutics.

[37]  T. Sugiyama,et al.  Novel epidermal growth factor receptor pathway mediates release of human β-defensin 3 from Helicobacter pylori-infected gastric epithelial cells. , 2016, Pathogens and disease.

[38]  Chao Lu,et al.  Probiotic supplementation does not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: a meta-analysis , 2016, Scientific Reports.

[39]  M. Emara,et al.  Emerging Role of Probiotics in the Management of Helicobacter Pylori Infection: Histopathologic Perspectives , 2016, Helicobacter.

[40]  J. Ball,et al.  An ancestral host defence peptide within human β-defensin 3 recapitulates the antibacterial and antiviral activity of the full-length molecule , 2015, Scientific Reports.

[41]  T. Pieber,et al.  Effects of high doses of vitamin D3 on mucosa-associated gut microbiome vary between regions of the human gastrointestinal tract , 2015, European Journal of Nutrition.

[42]  H. Szajewska,et al.  Systematic review with meta‐analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection , 2015, Alimentary pharmacology & therapeutics.

[43]  Wei Qian,et al.  Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. , 2015, World journal of gastroenterology.

[44]  J. Gisbert,et al.  Helicobacter pylori second‐line rescue therapy with levofloxacin‐ and bismuth‐containing quadruple therapy, after failure of standard triple or non‐bismuth quadruple treatments , 2015, Alimentary pharmacology & therapeutics.

[45]  Jeffrey L. Curtis,et al.  Analysis of the Upper Respiratory Tract Microbiotas as the Source of the Lung and Gastric Microbiotas in Healthy Individuals , 2015, mBio.

[46]  A. Sharara,et al.  Efficacy of reduced-dose regimen of a capsule containing bismuth subcitrate, metronidazole, and tetracycline given with amoxicillin and esomeprazole in the treatment of Helicobacter Pylori infection , 2015, United European gastroenterology journal.

[47]  Nayoung Kim,et al.  Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection , 2014, Gut and liver.

[48]  T. Deng,et al.  Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. , 2015, Internal medicine.

[49]  V. Papastergiou,et al.  Treatment of Helicobacter pylori infection: Past, present and future. , 2014, World journal of gastrointestinal pathophysiology.

[50]  P. Ruggiero Use of probiotics in the fight against Helicobacter pylori. , 2014, World journal of gastrointestinal pathophysiology.

[51]  Guoxin Zhang,et al.  The Effect of Probiotics Supplementation on Helicobacter pylori Eradication Rates and Side Effects during Eradication Therapy: A Meta-Analysis , 2014, PloS one.

[52]  Hongyu Zhang,et al.  Helicobacter pylori Dwelling on the Apical Surface of Gastrointestinal Epithelium Damages the Mucosal Barrier Through Direct Contact , 2014, Helicobacter.

[53]  Keng-Liang Wu,et al.  Levofloxacin-containing second-line anti-Helicobacter pylori eradication in Taiwanese real-world practice , 2014, Biomedical journal.

[54]  F. Hanisch,et al.  Human Trefoil Factor 2 Is a Lectin That Binds α-GlcNAc-capped Mucin Glycans with Antibiotic Activity against Helicobacter pylori* , 2014, The Journal of Biological Chemistry.

[55]  V. Papastergiou,et al.  Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance. , 2014, World journal of gastroenterology.

[56]  Glenn R. Gibson,et al.  The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic , 2014 .

[57]  Z. Tian,et al.  Participation of microbiota in the development of gastric cancer. , 2014, World journal of gastroenterology.

[58]  S. Fagarasan,et al.  Gut TFH and IgA: key players for regulation of bacterial communities and immune homeostasis , 2014, Immunology and cell biology.

[59]  M. Emara,et al.  Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial , 2014, Therapeutic advances in gastroenterology.

[60]  J. Versalovic,et al.  Lactobacillus reuteri Strain Combination In Helicobacter pylori Infection: A Randomized, Double-Blind, Placebo-Controlled Study , 2013, Journal of clinical gastroenterology.

[61]  S. Backert,et al.  Helicobacter pylori downregulates expression of human β-defensin 1 in the gastric mucosa in a type IV secretion-dependent fashion , 2013, Cellular microbiology.

[62]  S. K. Ogata,et al.  High Helicobacter pylori Resistance to Metronidazole and Clarithromycin in Brazilian Children and Adolescents , 2013, Journal of pediatric gastroenterology and nutrition.

[63]  R. Mattar,et al.  Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study , 2013, BMC Gastroenterology.

[64]  Mathilda Lindberg,et al.  Helicobacter pylori and the gastric microbiota. , 2013, Best practice & research. Clinical gastroenterology.

[65]  A. Seck,et al.  Primary antibiotic resistance and associated mechanisms in Helicobacter pylori isolates from Senegalese patients , 2013, Annals of Clinical Microbiology and Antimicrobials.

[66]  H. Goossens,et al.  Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption , 2012, Gut.

[67]  F. Fabbian,et al.  Helicobacter pylori Infection in Clinical Practice: Probiotics and a Combination of Probiotics + Lactoferrin Improve Compliance, But Not Eradication, in Sequential Therapy , 2012, Helicobacter.

[68]  B. Sheu,et al.  Probiotics‐Containing Yogurts Suppress Helicobacter pylori Load and Modify Immune Response and Intestinal Microbiota in the Helicobacter pylori‐Infected Children , 2012, Helicobacter.

[69]  M. Wiese,et al.  Immunomodulatory effects of Lactobacillous plantarum and Helicobacter pylori CagA⁺ on the expression of selected superficial molecules on monocyte and lymphocyte and the synthesis of cytokines in whole blood culture. , 2012, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[70]  C. Hassan,et al.  Probiotic multistrain treatment may eradicate Helicobacter pylori from the stomach of dyspeptics: a placebo-controlled pilot study. , 2012, Inflammation & allergy drug targets.

[71]  J. Gisbert,et al.  Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori , 2012, Clinical and experimental gastroenterology.

[72]  S. Kamiya Effect of Probiotics on Intestinal Infections , 2011 .

[73]  T. Wang,et al.  Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. , 2011, Gastroenterology.

[74]  Y. Takei,et al.  Risk for local recurrence of early gastric cancer treated with piecemeal endoscopic mucosal resection during a 10-year follow-up period , 2011, Surgical Endoscopy.

[75]  C. Hassan,et al.  Worldwide H. pylori antibiotic resistance: a systematic review. , 2010, Journal of gastrointestinal and liver diseases : JGLD.

[76]  H. Szajewska,et al.  Meta‐analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment , 2010, Alimentary pharmacology & therapeutics.

[77]  T. Alarcón,et al.  Detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies of pediatric patients by using a commercially available real-time polymerase chain reaction after NucliSens semiautomated DNA extraction. , 2010, Diagnostic microbiology and infectious disease.

[78]  Vincent Wai-Sun Wong,et al.  Bacterial Microbiota Profiling in Gastritis without Helicobacter pylori Infection or Non-Steroidal Anti-Inflammatory Drug Use , 2009, PloS one.

[79]  A. Zullo,et al.  Minimal inhibitory concentration (MIC) values and different point mutations in the 23S rRNA gene for clarithromycin resistance in Helicobacter pylori. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[80]  Y. Koga,et al.  Long‐term Administration of Probiotics to Asymptomatic Pre‐school Children for Either the Eradication or the Prevention of Helicobacter pylori Infection , 2009, Helicobacter.

[81]  M. Jarosz,et al.  Dietary and socio-economic factors in relation to Helicobacter pylori re-infection. , 2009, World journal of gastroenterology.

[82]  S. Brand,et al.  Expression of beta‐defensin 4 is increased in human gastritis , 2009, European journal of clinical investigation.

[83]  H. Jung,et al.  The Effects of Probiotics on PPI‐Triple Therapy for Helicobacter pylori Eradication , 2008, Helicobacter.

[84]  K. Fellermann,et al.  Probiotic lactobacilli and VSL#3 induce enterocyte β‐defensin 2 , 2008, Clinical and experimental immunology.

[85]  A. Dursun,et al.  Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylori Therapy: A Prospective Randomized Placebo‐Controlled Double‐Blind Study , 2007, Helicobacter.

[86]  T. Iino,et al.  Effect of Bifidobacterium bifidum fermented milk on Helicobacter pylori and serum pepsinogen levels in humans. , 2007, Journal of dairy science.

[87]  T Rokkas,et al.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report , 2006, Gut.

[88]  F. Mégraud,et al.  Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe , 2006, Gut.

[89]  P. Dhar,et al.  High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait , 2006, Alimentary pharmacology & therapeutics.

[90]  E. Ierardi,et al.  Lactobacillus reuteri therapy to reduce side‐effects during anti‐Helicobacter pylori treatment in children: a randomized placebo controlled trial , 2006, Alimentary pharmacology & therapeutics.

[91]  M. Valencia,et al.  Effect of a probiotic food as an adjuvant to triple therapy for eradication of Helicobacter pylori infection in children. , 2006, Nutrition.

[92]  S. Koletzko,et al.  Primary clarithromycin resistance to Helicobacter pylori and therapy failure in children: the experience in West Virginia. , 2006, Journal of pediatric gastroenterology and nutrition.

[93]  N. Tsuji,et al.  Human beta-defensin-3 induction in H. pylori-infected gastric mucosal tissues. , 2006, World journal of gastroenterology.

[94]  J. Amlerová,et al.  Effects of a Specially Designed Fermented Milk Product Containing Probiotic Lactobacillus casei DN-114 001 and the Eradication of H. pylori in Children: A Prospective Randomized Double-Blind Study , 2005, Journal of clinical gastroenterology.

[95]  M. Balsitis,et al.  Gastric epithelial anti-microbial peptides--histological correlation and influence of anatomical site and peptic ulcer disease. , 2005, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[96]  Deng-Chyang Wu,et al.  Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. , 2004, The American journal of clinical nutrition.

[97]  R. Hunt,et al.  Helicobacter pylori Public Health Implications , 2004, Helicobacter.

[98]  F. Russo,et al.  The Influence of Lactobacillus brevis on Ornithine Decarboxylase Activity and Polyamine Profiles in Helicobacter pylori‐Infected Gastric Mucosa , 2004, Helicobacter.

[99]  Farahnaz Nariman,et al.  Susceptibilities to Different Antibiotics of Helicobacter pylori Strains Isolated from Patients at the Pediatric Medical Center of Tehran, Iran , 2004, Journal of Clinical Microbiology.

[100]  E. Fontham,et al.  Impact of Helicobacter pylori Infection on Growth of Children: A Prospective Cohort Study , 2003, Journal of pediatric gastroenterology and nutrition.

[101]  M. Gotteland,et al.  Suppressive effect of frequent ingestion of Lactobacillus johnsonii La1 on Helicobacter pylori colonization in asymptomatic volunteers. , 2003, The Journal of antimicrobial chemotherapy.

[102]  Y. Pyun,et al.  Antagonism of Helicobacter pylori by bacteriocins of lactic acid bacteria. , 2003, Journal of food protection.

[103]  L. Piddock,et al.  The importance of efflux pumps in bacterial antibiotic resistance. , 2003, The Journal of antimicrobial chemotherapy.

[104]  A. Quinn,et al.  Modulation of host antimicrobial peptide (β-defensins 1 and 2) expression during gastritis , 2001 .

[105]  C. O'Morain,et al.  Helicobacter pylori Infection , 1994 .

[106]  T. Hirayama,et al.  Expression of human beta-defensin 2 (hBD-2) in Helicobacter pylori induced gastritis: antibacterial effect of hBD-2 against Helicobacter pylori. , 2001, Gut.

[107]  M. Konno,et al.  Iron-deficiency anemia associated with Helicobacter pylori gastritis. , 2000, Journal of pediatric gastroenterology and nutrition.

[108]  B. Trask,et al.  Cloning and characterization of two Toll/Interleukin-1 receptor-like genes TIL3 and TIL4: evidence for a multi-gene receptor family in humans. , 1998, Blood.

[109]  E. Kuipers,et al.  Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer , 1997, Alimentary pharmacology & therapeutics.

[110]  M. Blaser,et al.  Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. , 1995, Cancer research.

[111]  B. Marshall,et al.  UNIDENTIFIED CURVED BACILLI IN THE STOMACH OF PATIENTS WITH GASTRITIS AND PEPTIC ULCERATION , 1984, The Lancet.

[112]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.